Review of the Results of WT1 Peptide Vaccination Strategies for Myelodysplastic Syndromes and Acute Myeloid Leukemia from Nine Different Studies.
Review of the Results of WT1 Peptide Vaccination Strategies for Myelodysplastic Syndromes and Acute Myeloid Leukemia from Nine Different Studies.
复制标题
DOI：
10.3389/fimmu.2015.00036
复制
发表时间：
2015
影响因子：
7.3
通讯作者：
Rezvani K
中科院分区：
文献类型：
--
作者：
Di Stasi A;Jimenez AM;Minagawa K;Al-Obaidi M;Rezvani K
我们对2004年至2012年期间发表的骨髓增生异常综合征和/或急性髓系白血病（MDS/AML）患者中的9项WT 1肽疫苗临床试验的数据进行了系统回顾。共有51例患者符合分析条件。在不同机构的研究中，WT 1肽疫苗在MDS/AML患者中被证明是安全可行的。此外，观察到临床反应和临床获益，一些患者实现并维持长期缓解（超过8年）。在许多研究中注意到WT 1特异性T细胞的诱导与WT 1 mRNA水平的正常化/降低和无进展生存期之间的显著相关性。然而，需要更大规模的研究来证实这些结果。有趣的是，大多数试验报告接种前存在功能有限或不存在的WT 1特异性T细胞，接种后其频率和功能增加。总之，WT 1肽疫苗接种策略在这组异质性MDS/AML患者中是安全的。需要更大和更同质的研究或随机临床试验来量化WT 1肽疫苗对临床应答和长期生存的贡献。
We performed a systematic review of data from nine clinical trials of WT1 peptide vaccination in patients with myelodysplastic syndromes and/or acute myeloid leukemia (MDS/AML), published between 2004 and 2012. A total of 51 patients were eligible for analysis. Vaccination with WT1 peptides proved safe and feasible in patients with MDS/AML, in studies from different institutions. Additionally, clinical responses and clinical benefit were observed, with some patients achieving and maintaining remission long-term (more than 8 years). A significant correlation between induction of WT1-specific T cells and normalization/reduction of WT1 mRNA levels and progression-free survival was noted in a number of studies. However, larger studies are warranted to confirm these results. Interestingly, the majority of trials reported the presence of WT1-specific T cells with limited or absent functionality prior to vaccination, which increased in frequency and function after vaccination. In conclusion, WT1 peptide vaccination strategies were safe in this heterogeneous group of patient with MDS/AML. Larger and more homogeneous studies or randomized clinical trials are needed to quantify the contribution of WT1 peptide vaccines to clinical responses and long-term survival.
登录
查看更多内容
DOI：
10.1007/s00262-010-0929-7
发表时间：
2011-02
期刊：
Cancer immunology, immunotherapy : CII
影响因子：
--
作者：
Kuball J;de Boer K;Wagner E;Wattad M;Antunes E;Weeratna RD;Vicari AP;Lotz C;van Dorp S;Hol S;Greenberg PD;Heit W;Davis HL;Theobald M
通讯作者：
Theobald M
影响因子：
56.9
作者：
HABER, DA;PARK, S;GARVIN, AJ
通讯作者：
GARVIN, AJ
影响因子：
20.3
作者：
Gaiger, A;Reese, V;Cheever, MA
通讯作者：
Cheever, MA
影响因子：
20.3
作者：
Gao, LQ;Bellantuono, I;Stauss, HJ
通讯作者：
Stauss, HJ
影响因子：
3.7
作者：
Ali, Omar A.;Doherty, Ed;Emerich, Dwaine F.
通讯作者：
Emerich, Dwaine F.